DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection

BACKGROUND: A drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substantially advance malaria control. DSM265 is an experimental antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase. DSM265 shows in vitro act...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulyok, Mihály, Rückle, Thomas, Roth, Alexandra, Mürbeth, Raymund E, Chalon, Stephan, Kerr, Nicola, Samec, Sonia Schnieper, Gobeau, Nathalie, Calle, Carlos Lamsfus, Ibáñez, Javier, Sulyok, Zita, Held, Jana, Gebru, Tamirat, Granados, Patricia, Brückner, Sina, Nguetse, Christian, Mengue, Juliana, Lalremruata, Albert, Sim, B Kim Lee, Hoffman, Stephen L, Möhrle, Jörg J, Kremsner, Peter G, Mordmüller, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446410/
https://www.ncbi.nlm.nih.gov/pubmed/28363637
http://dx.doi.org/10.1016/S1473-3099(17)30139-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446410/
https://www.ncbi.nlm.nih.gov/pubmed/28363637
http://dx.doi.org/10.1016/S1473-3099(17)30139-1

Ejemplares similares